An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer

Moehler, Markus; Mueller, Annett; Hartmann, Jörg T.; Ebert, Matthias; Al‐Batran, Salah‐Eddin; Reimer, Peter; Weihrauch, Martin R.; Lordick, Florian; Trarbach, Tanja; Biesterfeld, Stefan; Kabisch, Maria; Wachtlin, Daniel; Galle, Peter R.

doi:10.1016/j.ejca.2011.04.006

Cited by 80 publications

(48 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…42,43 Sorafenib is a potent inhibitor of Raf and other receptor tyrosine kinase inhibitors in advanced gastric cancer. Sun et al 44 reported that sorafenib could inhibit the growth and angiogenesis of gastric carcinoma xenografts.…”

Section: Vascular Endothelial Growth Factor-targeted Therapymentioning

confidence: 99%

Progress in the treatment of advanced gastric cancer

et al. 2017

View full text Add to dashboard Cite

Gastric cancer is one of the most common malignant tumors in the digestive system. Surgery is currently considered to be the only radical treatment. As surgical techniques improve and progress is made in traditional radiotherapy, chemotherapy, and the implementation of neoadjuvant therapy, the 5-year survival rate of early gastric cancer can reach >95%. However, the low rate of early diagnosis means that most patients have advanced-stage disease at diagnosis and so the best surgical window is missed. Therefore, the main treatment for advanced gastric cancer is the combination of neoadjuvant chemoradiotherapy, molecular-targeted therapy, and immunotherapy. In this article, we summarize several common methods used to treat advanced gastric cancer and discuss the progress made in the treatment of gastric cancer in detail. Only clinical practice and clinical research will allow us to prolong the survival time of patients and allow the patients to truly benefit by paying attention to the individual patient characteristics, drug choice, and developing a reasonable and comprehensive treatment plan.

show abstract

Section: Vascular Endothelial Growth Factor-targeted Therapymentioning

confidence: 99%

Progress in the treatment of advanced gastric cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Grade 3-4 thrombocytopenia and neutropenia were reported in 34.6 % and 29.4 % of patients, respectively [56]. In another phase II trial, 52 patients with chemo-resistant advanced GC received sunitinib as a single agent, obtaining a median OS of 5.8 months [57]. These results do not support the role of single-agent sunitinib therapy in the second line of treatment for GC, and no further clinical trials in GC were launched.…”

Section: Sunitinibmentioning

confidence: 50%

Angiogenesis inhibitors in gastric and gastroesophageal junction cancer

et al. 2015

View full text Add to dashboard Cite

Despite significant improvements in systemic chemotherapy during the past two decades, the prognosis of patients with advanced gastric and gastroesophageal junction adenocarcinoma remains poor. Because of molecular heterogeneity, it is essential to classify tumors based on the underlying oncogenic pathways and to develop targeted therapies acting on individual tumors. Unfortunately, although a number of molecular targets have been studied, very few of these agents can be used in a clinical setting. In this review, we summarize the available data on anti-angiogenic agents in advanced/metastatic gastric cancer.

show abstract

“…This was potentially ascribed to differences in treatment patterns and outcomes in Asia compared to Europe, and in particular the Americas (19). Nonetheless, these results, concerns about bleeding with squamous cell carcinomas, and the modest single agent activity for sunitinib (response rates of 3.9-12%, but median progression free survival was less than 2 months, as second line therapy) (20,21) and sorafenib (response rate of 3%, but stable disease in and 56%, median progression free survival of 3.6% in refractory disease) (22) conspired to dampen the enthusiasm for anti-VEGF therapy in gastroesophageal cancers. In contrast to these disappointing early results, in the early part of this decade, novel anti-VEGF therapies i n c l u d i n g r a m u c i r u m a b , a m o n o c l o n a l a n t i b o d y inhibiting the VEGF receptor (VEGFR), and apatinib, an oral tyrosine kinase inhibitor of the VEGFR have been demonstrated to produce modest single agent response rates, but significantly increased survival in the second-line setting of patients with gastroesophageal junction adenocarcinoma.…”

Section: Vascular Endothelial Growth Factor (Vegf)mentioning

confidence: 90%

Beyond HER2: recent advances and future directions in targeted therapies in esophagogastric cancers

Hwang¹

2016

J. Gastrointest. Oncol.

View full text Add to dashboard Cite

Esophagogastric cancers (EGCa) are a leading cause of cancer related mortality worldwide. It has been recognized that they represent heterogenous diseases based on histology and anatomy. However, it is also increasingly evident that these are diverse malignancies based on genetic alterations, and this is increasingly making these diseases amenable to targeted therapies. While epidermal growth factor receptor (EGFR) and mTOR inhibitors have failed to prove effective in the treatment of advanced EGCa, vascular endothelial growth factor (VEGF) inihibitor have now been demonstrated to improve survival, at least in the 2nd line setting of adenocarcinomas. Other promising approaches are being investigated, including targeted therapies such as MET and FGFR inhibitors, as well as immunotherapy and agents that may affect synthetic lethality.

show abstract

An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer

Cited by 80 publications

References 46 publications

Progress in the treatment of advanced gastric cancer

Progress in the treatment of advanced gastric cancer

Angiogenesis inhibitors in gastric and gastroesophageal junction cancer

Beyond HER2: recent advances and future directions in targeted therapies in esophagogastric cancers

Contact Info

Product

Resources

About